Ortho-McNeil-Janssen Pharmaceuticals recently announced a three-year partnership with the Institute worth more than $85 million, according to the news provider.
READ MORE LEVAQUIN LEGAL NEWS
"This represents the first of what we expect to be a series of thematic collaborations that focus our tremendous scientific and translational firepower on major unmet medical problems," said Dr. John Reed, CEO of Sanford-Burnham. "Working in concert with strong partners, we can bridge the gap between early- and late-stage drug development."
According to its Web site, Sanford-Burnham employs nearly 900 scientists who strive to answer specific biological questions.